RecruitingPhase 1Phase 2NCT04429451

PSMA-specific CAR-T Cell Therapy

Phase I/II Clinical Trial of 4SCAR-PSMA T Cell Therapy Targeting PSMA Positive Malignancies

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment

100 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

PSMA Positive Tumors or Tumor Tissues

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.

Eligibility

Min Age: 1 YearMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called 4SCAR-PSMA T cells for people with psma positive tumors or tumor tissues. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICAL4SCAR-PSMA T cells

Infusion of 4SCAR-PSMA T cells at 10\^6 cells/kg body weight via IV

Locations(1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04429451

Related Trials

PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)

NCT070895504 locations